Pharma News

Biocon Ltd an innovation-led global biopharmaceuticals company and Equillium Inc, a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, announced that they have expanded their collaboration and license agreement for itolizumab to grant Equillium exclusive rights for developing and commercializing itolizumab in Australia and New Zealand.

Equillium had originally secured exclusive rights to develop and commercialize Biocon’s novel biologic, itolizumab, for the U.S. and Canada markets, in May 2017.

A treatment for neurological disorder, Huntington's disease, could be in the offing. A group of researchers from the Indian Institute of Technology-Indore have identified three chemical molecules that could potentiually be used to arrest its progression.

A common concern with oral vitamin B12 therapy is absorption especially in people suffering from anemia and gastrointestinal diseases. Researchers at the Council of Scientific and Industrial Research-Central Institute of Medicinal and Aromatic Plants (CSIR-CIMAP) have identified a plant extract that has shown potential in enhancing absorption of vitamin B12 through in vitro and in vivo bioassays.

The IIHMR University, Jaipur, has been ranked first amongst the cleanest higher educational institutions in India in the non-residential universities category in the Swachh Campus Rankings 2019 of Higher Education Institutions organized by the Ministry of Human Resource Development (MHRD), Govt. of India.

Eminence Business Media supports and work every day for empowering women and to create a platform for working women to network and grow, they organized the 2 nd Edition of its non-profitable “Remarkable Women Camaraderie 2019” on 29th November, 2019 at The Park Hotel, New Delhi.

Genentech, a member of the Roche Group  announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS). The study showed adding Tecentriq® (atezolizumab) to Cotellic ® (cobimetinib) and Zelboraf® (vemurafenib) helped to reduce the risk of disease worsening or death, compared to placebo plus Cotellic and Zelboraf.

This news can bring smiles on the faces of all those people who are suffering from obesity-induced diabetes. A group of researchers from Council of Scientific and Industrial Research- Center for Cellular and Molecular Biology (CSIR-CCMB) have shown the role of a protein that is responsible in increasing insulin action in obesity-induced diabetes.

Sun Pharma Advanced Research Company Ltd. (SPARC) announced that Abraxis Bioscience LLC. has dismissed the patent infringement complaint filed against SPARC regarding SPARC's New Drug Application for PICS (Paclitaxel Injection Concentrate for Suspension).

Zydus Cadila takes yet another step towards diabetes care with the launch of an affordable oral anti-diabetic agent, Vinglyn (Vildagliptin) & Vinglyn M (Vildagliptin plus metformin). The drug belongs to the class of oral anti-diabetic agents, known as DPP4 inhibitors, which have shown promise in achieving glycaemic control without deterioration in beta cell function and are one of the recent advancements in diabetes care and management. Vinglyn and Vinglyn M will be marketed by Zydus Healthcare Ltd.